ArticleTropical medicine and health2026
Development of a colorimetric RT-LAMP-based microfluidic device for SARS-CoV-2 detection.
Article in Tropical medicine and health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundDiagnosing COVID-19, caused by the coronavirus SARS-CoV-2, mainly involves detecting specific viral gene sequences. To effectively control highly contagious diseases, such as COVID-19, it is essential to develop quick, accurate, sensitive, and easy-to-use diagnostic methods for medical settings. The current gold standard, reverse transcription-quantitative polymerase chain reaction (RT-qPCR), requires specialized equipment and trained personnel and is typically conducted in dedicated laboratories. Loop-mediated isothermal amplification (LAMP) provides a rapid and simple alternative under isothermal conditions. In this study, we developed a colorimetric reverse transcription-loop-mediated isothermal amplification (RT-LAMP) assay for SARS-CoV-2 detection and integrated it into a microfluidic device.
methodsRT-LAMP primers targeting conserved regions of the SARS-CoV-2 envelope (E) and RNA-dependent RNA polymerase (RdRp) genes were designed. Hydroxy naphthol blue (HNB) was used as a color indicator for visual detection. The microfluidic device, fabricated from polydimethylsiloxane (PDMS), contained five reaction chambers. RNA samples extracted from nasopharyngeal swabs of COVID-19 patients were tested using the RT-LAMP microfluidic device. Detection performance of the device was assessed using RT-qPCR as the reference standard.
resultsAmong 86 RNA samples, 66 were RT-qPCR positive and 20 were negative. The RT-LAMP microfluidic device achieved 100% specificity (95% CI 83.2-100%) and an overall sensitivity of 75.8% (95% CI 63.6-85.5%) for samples with Ct ≤ 35. Sensitivity correlated with viral load, showing 100% for samples with Ct ≤ 25, 88.6% for Ct ≤ 30, and 50% for 30 < Ct ≤ 35.
conclusionsThe colorimetric RT-LAMP-based microfluidic device enables simple, rapid, and reliable detection of SARS-CoV-2 RNA with high specificity and sensitivity. The device enables visual detection of results and requires only simple equipment, making it suitable as a practical molecular detection tool for point-of-care and resource-limited settings. In terms of detection performance, our findings, when considered alongside previously published data, indicate that the sensitivity and specificity of the device are comparable to or exceed those of lateral flow tests commonly used for point-of-care COVID-19 diagnostics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.